15th February 2011 - New research


The Lancet Neurology, Early Online Publication, 10 February 2011 (Robert A Hauser, Marc Cantillon, Emmanuelle Pourcher, Federico Micheli, Vincent Mok, Marco Onofrj, Susan Huyck, Kenneth Wolski)  Complete abstract

Preladenant is an adenosine 2A (A2A) receptor antagonist. Researchers aimed to assess the efficacy and safety of Preladenant in patients with Parkinson's disease and motor fluctuations who were receiving L-dopa and other Parkinson's Disease drugs. Patients were assigned to receive 1mg, 2mg, 5mg, or 10 mg oral Preladenant twice daily, or matching placebo for 12 weeks. There was no significant change as a result of taking 1mg or 2mg of Preladenant. Average daily off time was reduced by 60 minutes using 5mg Preladenant. Average daily off time was reduced by 72 minutes using 10mg Preladenant. The most common adverse events for were worsening of Parkinson's Disease, somnolence, dyskinesia, nausea, constipation, and insomnia. However, the frequency of these adverse events was little different from those people taking the placebo. So it is doubtful whether they are of significance. The authors consequently believe that 5mg Preladenant and 10 mg Preladenant twice daily might be clinically useful to reduce off time in patients with Parkinson's disease and motor fluctuations. For more information go to the News release.
For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports





2006-2010  Viartis
2015-06-28 23:59:37
[email protected]